Alberto L. Dubrovsky

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

Journal: Journal of neurology

Published: July 31, 2025

Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

Journal: Journal of neurology

Published: February 22, 2024

Prognostic significance of ACTN3 genotype in Duchenne muscular dystrophy: Findings from an Argentine patient cohort.

Prognostic significance of ACTN3 genotype in Duchenne muscular dystrophy: Findings from an Argentine patient cohort.

Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

Published: February 16, 2024

The difficult path to diagnosis of the patient with spinal muscular atrophy.

The difficult path to diagnosis of the patient with spinal muscular atrophy.

Journal: Archivos argentinos de pediatria

Published: October 26, 2022

Theragnosis for Duchenne Muscular Dystrophy.

Theragnosis for Duchenne Muscular Dystrophy.

Journal: Frontiers in pharmacology

Published: December 31, 2020

The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease.

The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease.

Journal: Orphanet journal of rare diseases

Published: September 10, 2019

HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypes.

HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypes.

Journal: Journal of neurology

Published: March 23, 2019

Argentine consensus on late-onset Pompe's disease

Argentine consensus on late-onset Pompe's disease

Journal: Medicina

Published: September 05, 2018

Intraneural perineuriomas: diagnostic value of magnetic resonance neurography.

Intraneural perineuriomas: diagnostic value of magnetic resonance neurography.

Journal: Journal of the peripheral nervous system : JPNS

Published: September 01, 2017

A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.

A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.

Journal: Neurology

Published: March 21, 2017

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.

Journal: Neuromuscular disorders : NMD

Published: March 21, 2017

Thoracic Outlet Syndrome: is it always a surgical condition? Analysis of a series of 31 cases operated by the supraclavicular route

Thoracic Outlet Syndrome: is it always a surgical condition? Analysis of a series of 31 cases operated by the supraclavicular route

Journal: Surgical neurology international

Published: July 04, 2013

Showing 1-12 of 17

Last Updated: 09/26/2026